Figure 2
Figure 2. Pretreatment Bcl-2/IgH status and level. (A) Kaplan-Meier plots of PFS according to the pretreatment Bcl-2/IgH status: Bcl-2/IgH positive vs Bcl-2/IgH negative. (B) Kaplan-Meier plots of PFS according to the pretreatment Bcl-2/IgH level: negative vs below median vs above median (Bcl-2/IgH level of negative vs <0.0699 vs >0.0699) and high vs intermediate vs low (Bcl-2/IgH level of >1 vs 0.1-1 vs <0.1). (C) Pretreatment Bcl-2/IgH level and FLIPI risk groups: low risk (score 0-1), intermediate risk (score 2), and high risk (score >3-5). Horizontal bars indicate the median Bcl-2/IgH level. Diamonds correspond to individual sample values. (D) Kaplan-Meier plots of PFS for FLIPI risk groups low, intermediate, and high. PFS for intermediate- and high-risk patients was further calculated according to the pretreatment Bcl-2/IgH levels.

Pretreatment Bcl-2/IgH status and level. (A) Kaplan-Meier plots of PFS according to the pretreatment Bcl-2/IgH status: Bcl-2/IgH positive vs Bcl-2/IgH negative. (B) Kaplan-Meier plots of PFS according to the pretreatment Bcl-2/IgH level: negative vs below median vs above median (Bcl-2/IgH level of negative vs <0.0699 vs >0.0699) and high vs intermediate vs low (Bcl-2/IgH level of >1 vs 0.1-1 vs <0.1). (C) Pretreatment Bcl-2/IgH level and FLIPI risk groups: low risk (score 0-1), intermediate risk (score 2), and high risk (score >3-5). Horizontal bars indicate the median Bcl-2/IgH level. Diamonds correspond to individual sample values. (D) Kaplan-Meier plots of PFS for FLIPI risk groups low, intermediate, and high. PFS for intermediate- and high-risk patients was further calculated according to the pretreatment Bcl-2/IgH levels.

Close Modal

or Create an Account

Close Modal
Close Modal